

*SOURCE: Neptune Technologies & Bioresources Inc.*

## **Neptune to Hold Conference Call to Discuss Fourth Quarter and Fiscal 2013 Results**

**Laval, Québec, CANADA – May 9, 2013** – Neptune Technologies & Bioresources Inc. (“**Neptune**”) (NASDAQ.NEPT - TSX.NTB) will be holding a conference call on Thursday May 23 at 9:00 am ET to present its results for the fourth quarter and fiscal year ended February 28, 2013. The Company will also be providing an update on the status of its previously disclosed action plan to resume operations and supply customers.

The conference call hosts will be Henri Harland, President & CEO and André Godin, CFO.

To access the conference call within Canada & the U.S., dial toll-free 1-877-380-5664. Outside Canada and the U.S., dial 1-631-813-4882.

### **Conference call details:**

Conference Topic: Neptune Technologies & Bioresources Fourth Quarter and Fiscal Year Ended February 28, 2013 Results Call  
Conference ID: 70455786  
Time: 9:00 AM Eastern Time

Management will accept questions related to the financial results and its operations by telephone during the Q&A period at the end of the presentation. Questions can also be forwarded in advance or during the presentation to [f.harland@neptunebiotech.com](mailto:f.harland@neptunebiotech.com).

An archived recording of the conference call will be available on Neptune’s website ([www.neptunebiotech.com](http://www.neptunebiotech.com)) shortly after the call.

Neptune’s audited consolidated financial statements for the period ended February 28, 2013 and related MD&A will be made available on SEDAR at [www.sedar.com](http://www.sedar.com), on EDGAR at [www.sec.gov/edgar.shtml](http://www.sec.gov/edgar.shtml) and on Neptune’s website at <http://www.neptunebiotech.com> prior to the conference call.

### **About Neptune Technologies & Bioresources Inc.**

Neptune is a biotechnology company engaged primarily in the development and commercialization of marine-derived omega-3 polyunsaturated fatty acids, or PUFAs. Neptune has a patented process of extracting oils from Antarctic krill, which omega-3 PUFAs are then principally sold as bulk oil to Neptune’s distributors who commercialize them under their private label primarily in the U.S., European and Asian nutraceutical markets. Neptune’s lead products, Neptune Krill Oil (NKO®) and ECOKRILL Oil (EKO™), generally come in capsule form and serve as a dietary supplement to consumers.

Through its subsidiaries Acasti Pharma and NeuroBioPharm, in which Neptune respectively holds 57% and 96% of the voting rights, Neptune is also pursuing opportunities in the medical food and prescription drug markets. Acasti and NeuroBio respectively focus on the research and development of safe and therapeutically effective compounds for highly prevalent atherosclerotic conditions, such as cardiometabolic disorders and cardiovascular diseases, and for neurodegenerative and inflammation related conditions. Acasti’s lead prescription drug candidate is CaPre®, a purified high omega-3 phospholipid concentrate derived from krill oil

being developed to address the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia, which is characterized by abnormally high levels of triglycerides.

### **Forward Looking Statements**

*Certain statements included in this press release may be considered forward-looking information within the meaning of Canadian securities laws and forward-looking statements within the meaning of U.S. federal securities laws, both of which we refer to as forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that may cause results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Neptune's current beliefs as well as assumptions made by and information currently available to Neptune and relate to, among other things, Neptune's strategy, strategic goals, research and development activities, research and clinical testing outcome, future operations, future financial position, future revenues/results, projected costs, prospects and plans and objectives of management.*

*Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Neptune in its amended and restated annual information form dated September 11, 2012, in its press release announcing an action plan to resume operations and supply customers dated November 26, 2012 and in its other public securities filings available at [www.sedar.com](http://www.sedar.com) and [www.sec.gov/edgar.shtml](http://www.sec.gov/edgar.shtml), actual events may differ materially from current expectations. Except as required by law, Neptune disclaims any intention or obligation to update or revise any forward-looking statements.*

#### **Neptune Contact:**

Neptune Technologies & Bioresources Inc.  
André Godin, CFO  
+1.450.687.2262  
[a.godin@neptunebiotech.com](mailto:a.godin@neptunebiotech.com)  
[www.neptunebiotech.com](http://www.neptunebiotech.com)

#### **Howard Group Contact:**

Dave Burwell  
+1.888.221.0915  
[dave@howardgroupinc.com](mailto:dave@howardgroupinc.com)  
[www.howardgroupinc.com](http://www.howardgroupinc.com)